User: Guest  Login
Title:

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.

Document type:
Article; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Author(s):
Choi, Bryan D; Yu, Xiaoling; Castano, Ana P; Darr, Henia; Henderson, Daniel B; Bouffard, Amanda A; Larson, Rebecca C; Scarfò, Irene; Bailey, Stefanie R; Gerhard, Genevieve M; Frigault, Matthew J; Leick, Mark B; Schmidts, Andrea; Sagert, Jason G; Curry, William T; Carter, Bob S; Maus, Marcela V
Abstract:
Despite remarkable success in the treatment of hematological malignancies, CAR T-cell therapies for solid tumors have floundered, in large part due to local immune suppression and the effects of prolonged stimulation leading to T-cell dysfunction and exhaustion. One mechanism by which gliomas and other cancers can hamper CAR T cells is through surface expression of inhibitory ligands such as programmed cell death ligand 1 (PD-L1). Using the CRIPSR-Cas9 system, we created universal CAR T cells re...     »
Journal title abbreviation:
J Immunother Cancer
Year:
2019
Journal volume:
7
Journal issue:
1
Fulltext / DOI:
doi:10.1186/s40425-019-0806-7
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/31727131
TUM Institution:
Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie
 BibTeX